IXICO plc (IXI.L)

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.